History Highlight

2019

04 Completion of Plant
02 Pre-clinical trial product & Start pro-clinical study(Feb. 15)
Issued new shares(44million)
 

2018

12 Process development for Pre-clinical trial product
Issued new shares(19million)
11 Characterization of Botulinum Toxin
10 Contracted with Pre-Clinical Trial CRO (Biotoxtech.co.Ltd)
 

2017

02 Animal experimental facilities registration
01 Completed reporting of high-risk pathogen treatment research facility (No. KCDC-17-2-01)
Botulinum movement and retention report Korea Centers for Disease Control and Prevention (Management No.: 4-026-CBB-CO-040)
 

2016

12 Extension of expansion of R&D Center (in Hyangnam-eup, Hwaseong-si, Gyeonggi-do)
08 Acquire license of medical device manufacturing (for export)
Acquire license of medical device manufacturing
07 Took over MEDICA Korea Co., Ltd. (USD 33million)
04 Established Seoul office (Diplomatic center)
Transferred PROTOX HQ. (Anseong GMP Factory)
03 Took over Anseong GMP factory (10,000m2) as subsidiary of DSK
 

2015

12 Authorized venture company (Korea Technology Finance Corporation)
09 Established PROTOX CO., LTD.